Handbook on Private Drug Plans 1997-2000

Private sector drug plan managers are under increasing pressure to obtain the greatest value for their drug plan dollars. Drug plans are no longer viewed as a simple benefit, but rather as one of many tools contributing to company productivity and growth.

With a research grant from Merck Frosst Inc., Brogan Inc. has released the third edition on the factors which affect the cost of private drug plans:



For this third edition, we have increased the scope of the research to provide a better understanding and benchmarking of private drug plan costs. Specifically, we will be able to provide findings from both a national and regional perspective [Atlantic, Quebec, Ontario and Western regions]. New elements in this latest report also include a more in-depth analysis of selected diseases such as depression, cardiovascular disorders and diabetes.

To request a free copy of this study, call 613.599.0711 or click here to fill out our request form.